Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Allogene Therapeutics, Inc. ALLO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
43/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$29.00
+1171.9%

Allogene Therapeutics, Inc. (ALLO) is a Biotechnology company in the Healthcare sector, currently trading at $2.28. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ALLO = $29 (+1171.9% upside).

Valuation: ALLO trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.09.

Net income is $191M (loss), growing at +17%/yr. Net profit margin is 0% (thin). Gross margin is -873986.4% (-709735.8 pp trend).

Balance sheet: total debt is $75M against $293M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 7.93 (strong liquidity). Debt-to-assets is 18%. Total assets: $416M.

Analyst outlook: 19 / 29 analysts rate ALLO as buy (66%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 6/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$29.00
▲ 1171.93% Upside
Average Price Target
Based on 29 Wall Street analysts offering 12-month price targets for Allogene Therapeutics, Inc., the average price target is $29.00, with a high forecast of $55.00, and a low forecast of $7.00.
Highest Price Target
$55.00
Average Price Target
$29.00
Lowest Price Target
$7.00

ALLO SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 62/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 6/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALLO

✓
VALUE Pass
62/100
ALLO trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25). Forward PEG 2.09 — overvalued. Analyst consensus target is $29, implying +1171.9% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ALLO: -72%/yr revenue is, +17%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ALLO: Debt-to-Equity (D/E) ratio 0.26 (conservative), Current ratio is 7.93 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
6/100
ALLO: Gross margin is -873986.4% (-709735.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 6/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 19 / 29 analysts rate ALLO as buy (66%). Analyst consensus target is $29 (+1171.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.86-2.8
Volume41.23M
Avg Volume (30D)7.22M
Market Cap$555.81M
Beta (1Y)0.54
Share Statistics
EPS (TTM)-0.87
Shares Outstanding$220.62M
IPO Date2018-10-11
Employees226
CEODavid D. Chang
Financial Highlights & Ratios
Gross Profit$-12.36M
EBITDA$-194.57M
Net Income$-190.89M
Operating Income$-206.93M
Total Cash$250.21M
Total Debt$75.05M
Net Debt$23.36M
Total Assets$415.91M
Price / Earnings (P/E)-2.6
Analyst Forecast
1Y Price Target$33.50
Target High$55.00
Target Low$7.00
Upside+1,369.3%
Rating ConsensusBuy
Analysts Covering29
Buy 66% Hold 28% Sell 7%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS0197701065

Price Chart

Track all markets on TradingView
ALLO
Allogene Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.86 52WK RANGE 2.80

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 BEAM
BEAM
Beam Therapeutics Inc.
$30.30
+0.40%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.78
+3.65%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 VERV
VERV
Verve Therapeutics, Inc.
$11.13
+0.27%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message